Compare AU
Compare DRUG vs. IXJ
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the iShares Global Healthcare ETF (IXJ). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | IXJ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 64 | 256 |
Median incremental investment | $990.50 | $1,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,963.48 | $1,740.44 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | IXJ | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | IXJ.AX was created on 2001-11-13 by iShares. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large-, mid- or smallcapitalisation stocks |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | Eli Lilly and Company (8.25 %) UnitedHealth Group Incorporated (5.81 %) Johnson & Johnson (4.72 %) |
Top 3 industries | Other (77.25 %) Communication Services (33.53 %) Health Care (22.59 %) | Other (99.98 %) Communication Services (0.02 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (99.97 %) |
Management fee | 0.57 % | 0.46 % |
Key Summary
DRUG | IXJ | |
|---|---|---|
Issuer | BetaShares | iShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | S&P Global 1200 Healthcare Sector Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.46 % |
Price | $7.64 | $133.88 |
Size | $166.049 million | $1.313 billion |
10Y return | N/A | 88.91 % |
Annual distribution yield (5Y) | 1.89 % | 1.26 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 11/03/2009 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | IXJ | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 64 | 256 |
Median incremental investment | $990.50 | $1,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,963.48 | $1,740.44 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | IXJ | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | IXJ |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |